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Background: Studies suggest that expectations powerfully shape clinical outcomes. For subjective outcomes in
adequately blinded trials, health improvements are substantial and largely explained by non-specific factors.
The objective of this study was to investigate if unblinding in randomized controlled trials (RCTs) is associated with
enhanced placebo effects for intervention groups and nocebo effects for placebo groups. For these effects, a
secondary objective was to explore potential moderating factors.
Methods: We included RCTs that investigated the efficacy of phosphodiesterase-5 (PDE-5) inhibitors for male
erectile dysfunction by comparing one PDE-5 inhibitor to placebo. In addition, to be included studies must have
reported scores for change from baseline, or baseline and final International Index of Erectile Functioning-Erectile
Functioning domain score (IIEF-EF), and be published in either English, French, Dutch, or German.
We searched for both published and unpublished relevant trials using PUBMED, EMBASE, the Cochrane Central Register
of Controlled Trials, a clinical trials register (clinicaltrials.gov) and the Food and Drug Administration clinical reviews
through March 2012.
We evaluated the blinding status of trials with the Cochrane Risk of Bias Tool, using the domains of allocation
sequence concealment, blinding of participants, healthcare providers and outcome assessors. Across these four
domains, studies that scored low risk of bias were judged to be adequately blinded and studies that scored unclear or
high risk of bias were judged to be inadequately blinded.
Results: We included 110 studies (205 journal publications and 2 unpublished sources) that involved 23,877
participants; 93 (85%), 51 (46%), 93 (85%) and 93 (85%) studies were assessed with an unclear risk of bias for allocation
concealment, blinding of participant, blinding of caregiver and blinding of outcome assessor, respectively. None of the
studies reported testing of blinding.
None of the 205 journal publications provided sufficient details to assess allocation concealment, blinding of
participants, caregivers and outcome assessors. After contacting authors for additional information, we judged five
studies to be adequately (n = 1,202) and 16 to be inadequately (n = 3,006) blinded. The IIEF-EF score for placebo groups
in adequately blinded trials versus inadequately blinded trials was 1.92 points (95% CI, 0.64 to 3.20) versus 1.56 (95% CI,
0.93 to 2.20), respectively. The IIEF-EF score for intervention groups in adequately blinded trials versus inadequately
blinded trials was 9.40 (95% CI, 6.96 to 11.83) versus 8.33 (95% CI, 7.29 to 9.37), respectively. In a secondary analysis, prior
experience with the drug affected the scores; in placebo groups with participants naïve to the intervention the score
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was 2.89 (95% CI, 2.33 to 3.45) versus -0.11 (95% CI, -2.06 to 1.84) with participants having prior experience. In the
intervention groups, these scores were 7.99 (95% CI, 6.85 to 9.14) versus 8.33 (95% CI, 7.51 to 9.16), respectively.
Unblinding lowered placebo scores (creating a nocebo effect) by 19% (0.33 points; 95% CI, -0.96 to 1.62). Unblinding
lowered intervention scores by 11% (1.0; 95% CI, -1.35 to 3.47). The results provided no conclusive evidence for nocebo
or enhanced placebo effects. Patients taking a PDE-5 inhibitor for the first time experience a larger placebo effect that
accounts for 35% of the total effect.
Conclusions: Given the overall poor reporting of blinding in clinical trial reports and the small number of trials that
could be rated as adequately or inadequately blinded, we could not draw any robust conclusions about the existence
or absence of nocebo and enhanced placebo effects. A large placebo effect was found for patients taking PDE-5
inhibitors for the first time. It was not clear if previous exposure to the drug impacted trial blinding.
We found clear evidence that studies assessing a subjective continuous outcome fail to report on measures
taken to secure double blinding. Although we observed a trend for the presence of a nocebo effect, there was
insufficient evidence to quantify its impact on expectations. RCTs with patients with no prior experience with
PDE-5 inhibitors reported larger placebo effects and possibly these studies were better blinded. Future research
should further investigate the factors that contribute to blinding and their impact on health outcomes in randomized
trials of subjectively assessed conditions. This research is part of a PhD project and has no external funding. The authors
have no competing interests to declare.
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Treatment efficacyBackground
A particular treatment effect may exert both non-specific
and specific effects. A non-specific treatment effect is an
outcome that does not arise according to an intended
mechanism of action. This can be a response to placebo
or reflection of spontaneous symptom improvement. A
placebo is usually thought of as a sugar pill, but placebos
can come in several forms; they may be things (syringes,
medical devices), rituals (anamnesis, ingestion of drugs),
places (hospital, doctor’s office), relationships (with doctor,
self-help group) or medical beliefs to suggestive wordings
[1]. The response to a placebo can be either positive for
the outcome of interest, defined as a placebo effect, or
negative for the outcome of interest, defined as a nocebo
effect.
These effects are commonly explained by expectancy and
conditional learning [2]. These two concepts overlap so, for
convenience, we will use the term ‘expectancy’ to describe
the mechanism behind placebo and nocebo effects.
Studies have shown that expectations can induce very
powerful effects. In an experiment with an opioid pain-
killer, remifentanil, the presence of positive treatment
expectancies was found to double the analgesic effect.
Conversely, negative treatment expectancies interfered
with the analgesic potential of the painkiller to the ex-
tent that the analgesic effect was completely abolished
[3]. In a double-blind sham surgery trial, investigating
a new surgical transplant technique for treatment of
Parkinson’s disease, sham and real surgery interventions
were equally effective. However, participants who thoughtthey received the transplant reported better quality of life
[4]. It seems that positive expectations were triggered by
the perceived benefit from the treatment.
To control for the effects of expectations, the double-
blind randomized controlled trial (RCT) design is com-
monly employed to study a novel intervention for its
specific effects. Because neither participants nor investi-
gators know who gets the intervention or the placebo,
expectancies are balanced across groups. Double blind-
ing makes groups comparable so that specific and non-
specific treatment effects (that is, the effect size of the
placebo group) can be ascertained with less potential for
bias. Both intervention and placebo groups may have
two important expectations in common: ‘I get the inter-
vention or the placebo’ and ‘the intervention under study
can cure my problem’.
However, there is little evidence that RCTs are, in fact,
double-blinded [5]. Many factors can undermine double-
blinded methodology, including poor randomization
methods, imperfect concealment of allocation, and the
use of a placebo that is distinguishable from the inter-
vention. Furthermore, in RCTs of pharmacological
agents, the presence of side effects may allow partici-
pants or investigators to guess correctly who has been
allocated to intervention or placebo [6]. Therefore, the
use of an active placebo that mimics some of the inter-
vention’s side effects has been advocated to improve
clinical trial blinding.
If an RCT is not adequately double-blinded, partici-
pants and investigators will know who gets what type of
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anced among treatment arms. A participant allocated to
the intervention would have altered expectations: ‘I get
the intervention’ and ‘the intervention under study can
cure my problem.’ This enhances the participant’s prior
expectations and can generate an enhanced placebo ef-
fect. For participants receiving the placebo, expectations
could be ‘I get the placebo’ and ‘the intervention under
study can cure my problem.’ This can lower participants’
expectations and generate a nocebo effect.
This review tested the hypothesis that unblinding in
RCTs is associated with enhanced placebo effects for inter-
vention groups and nocebo effects for placebo groups. We
investigated this research question by conducting a meta-
epidemiological study of phosphodiesterase-5 (PDE-5)
inhibitors. For many years, this treatment has been an
established baseline treatment for erectile dysfunction
(ED). Numerous trials, overviews, and systematic re-
views provide evidence for the efficacy and safety of
sildenafil, tadalafil, and vardenafil [7]. There is also a
growing evidence base for the newer molecules mirode-
nafil, udenafil, lodenafil, and avanafil. The PDE-5 inhibi-
tors have been tested in many different populations,
including those with broad-spectrum and specific comor-
bid conditions. The role of treatment expectations is of
particular relevance to these medications for several rea-
sons. Firstly, the evidence for efficacy relies solely on sub-
jectively assessed outcomes, such as self-administered
questionnaires (International Index of Erectile Function-
ing (IIEF)), event logs, and a Global Efficacy Question
(GEQ) [8]. RCTs that use these subjective outcome mea-
sures are especially vulnerable to unblinding: non-blinded
RCTs report 25% higher estimates of treatment effects
than their blinded counterparts [9]. Whether this can be
explained by nocebo effects in placebo groups or enhanced
placebo effects for intervention groups was not reported.
Secondly, since PDE-5 inhibitors are a well-tolerated and
effective treatment for ED, initial expectations to treat this
common male sexual problem are high for doctors, pa-
tients, and drug companies. Lastly, as suggestion can create
expectancies [10], the domain of male sexual performance
is a very suggestive domain, where expectations can play a
fundamental role.
This meta-epidemiological study explored magnitude
of expectancy and its moderating factors in RCTs. If the
mechanisms moderating placebo effects such as expecta-
tions can be used in a non-deceptive way to produce
clinically advantageous outcomes, then it may be pos-
sible to incorporate these mechanisms into evidence-
based healthcare decision-making.
Methods
We followed our published, open access pre-specified
protocol during the systematic review [11]. A detailedmethodology can be found as a supplemental file. We
updated a dataset from an earlier published systematic
review on PDE-5 inhibitors [12]. We restricted our
search to English, French, Dutch, or German reports
from the three agents approved by the Food and Drug
Administration (FDA): sildenafil, vardenafil, and tadalafil.
Our search strategy employed a combination of con-
trolled vocabulary (MeSH terms) and free text words.
Three concepts were combined (AND): the intervention
concept ‘PDE-5 inhibitor’, the disease concept ‘erectile
dysfunction,’ and the design concept ‘RCT’. Strategies
were adapted to search individual electronic databases.
The last search was performed on 23 March 2012.
One reviewer (FF) manually screened the titles and ab-
stracts. The full texts of potentially relevant reports were
obtained. Multiple reports for the same study were
linked to determine eligibility. Two reviewers (FF, GEB)
screened full, unblinded texts. Disagreements were re-
solved by discussion.
We included RCTs that compared one PDE-5 inhibitor
to placebo to investigate the efficacy of PDE-5 inhibitors
in treating male ED. Studies had to report scores for
change from baseline, or baseline and final IIEF erectile
functioning domain (EF).
We used pilot-tested, electronic forms to extract data
and assess risk of bias (ROB) of all included study reports.
Two reviewers (FF, GEB) assessed blinding using four do-
mains of the Cochrane’s ‘risk-of-bias’ tool that relate to
blinding: allocation concealment, blinding of patient,
blinding of caregiver, and blinding of outcome assessor
[13]. In addition, the assessment included an evaluation of
sequence generation, intention-to-treat (ITT) analysis and
comparability of intervention and placebo groups. For
each included study, we rated the ROB domains as
low, high, or unclear. Disagreements were resolved by
discussion.
To assess effect sizes, the most commonly used con-
tinuous subjective outcome in efficacy studies of PDE-5
inhibitors was used, the International Index of Erectile
Functioning-Erectile Functioning domain score (IIEF-EF)
[14]. We also assessed a dichotomous subjective outcome,
the GEQ, to confirm consistency of the effect.
As a secondary objective, we explored moderating var-
iables of placebo and intervention effect estimates that
may explain enhanced placebo and nocebo effects. Of
particular interest were prior experience with medica-
tion, drug side effects, study run-in period with placebo,
sample size, geographical location of the study, single-
or multi-center study, parallel or cross-over study, pro-
portion of psychogenic etiology, prostate cancer or
spinal cord injury, funding source, publication year,
baseline disease severity, disease duration, study dur-
ation, type of PDE-5 inhibitor, commercial funding and
number of follow-ups after baseline assessment. Rationales
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lished protocol.
For the treatment effect size, the change from baseline
IIEF-EF score for intervention group and placebo group
were used. If only final and baseline IIEF-EF scores were
reported, we assumed change scores to be final-minus-
baseline scores.
For placebo and intervention groups separately, we
used a dichotomous subjective outcome (GEQ) and the
two most common adverse events (AEs) reported (head-
ache and flushing). We calculated risk ratios with 95%
CIs. For GEQ, all randomized participants were included
in the analysis, irrespective of how the authors of the re-
port defined their ITT sample.
We imputed missing data, such as standard deviation,
based on other available data, such as standard error,
95% CI, t value, or P value. If imputation of missing data
was not possible, we contacted the original investigators
to request missing data. If there was no response, we
used data from matched studies.
We performed meta-analysis on studies using generic
inverse variance. We used a random-effects model be-
cause the included studies showed considerable clinical
(broad-spectrum and specific comorbid populations; dif-
ferent PDE-5 inhibitors) and methodological (study de-
sign, ROB) heterogeneity. The analysis included all
parallel RCTs and a separate analysis included crossover
RCTs. Regression analysis showed uncertain, very small
effect size differences between crossover and parallel
studies, so we decided to pool data from both study
designs.
For every individual ROB domain, we grouped studies
with low ROB and studies with unclear or high ROB.
Studies that have a low ROB across all four ROB do-
mains were considered adequately blinded. Studies that
have a high ROB in at least one ROB domain or studies
that have an unclear ROB across all four ROB domains
were considered inadequately blinded. Adequately blinded
studies were pooled and compared with inadequately
blinded studies. For both groups, we calculated pooled
intervention and placebo effect. We quantified the magni-
tude of enhanced placebo effects as the difference in inter-
vention effect estimates among studies with inadequate
blinding and studies with adequate blinding. Similarly,
the magnitude of nocebo effects was quantified as the
difference in placebo effect estimates among studies
with inadequate and adequate blinding. Using RevMan,
between-meta-analysis heterogeneity variance was calcu-
lated to express the variability in bias with P value and
identified visually using a forest plot [15]. The magnitude
of heterogeneity was assessed by calculating I2 and con-
firmed with a chi-square test. Blinding status is likely to
be associated with other variables that also influence
within-group intervention and placebo effect estimates.Using meta-regression analysis, we investigated baseline ED
severity and publication year as possible confounders.
Inverse variance weighted regression analysis was done
using Wilson macros (David B. Wilson, 4400 University
Drive, MS 4 F4 Fairfax, VA 22030, United States) and
SPSS 20 (IBM, 1 New Orchard Road, Armonk, New
York 10504-1722, United States) to measure the impact
of study, intervention, and patient factors on placebo
and intervention effects separately [16]. A restricted
maximum likelihood random effects variance compo-
nent model was chosen to allow for residual variance.
For multiple regression, a forward stepwise strategy with
a lax entry criterion was used. Differences between
groups were quantified with a 95% CI and then qualified
statistically using a t test of no difference with P value.
We had many studies with missing SDs. Therefore, ana-
lyzed groups of studies included RCTs with reported SD,
and a random set of studies with missing SD was allowed
up to 33% of the total sample. SDs were substituted with
SDs from matched studies on sample size.
Results
We retrieved 3,622 records by electronic database searches.
From our previous study we included 17 additional records
that met screening criteria. After linking reports to individ-
ual studies, 173 studies were considered as potentially eli-
gible. There was good agreement among reviewers as to
what studies to include and exclude (Kappa statistic 0.85).
An overview can be found in the PRISMA study flow dia-
gram (Figure 1).
We excluded 63 studies, mostly because the primary
outcome (IIEF-EF score) was missing (see Additional file
1). Thus, we included 110 studies (see Additional file 2).
Of these, 107 studies were publicized in 205 journal
publications, and three studies were not publicized (two
in FDA records and one in ClinicalTrials.gov). Further-
more, 98 (89%) were parallel designed, 89 (81%) were
commercially funded, 55 (50%) tested sildenafil, 10 (9%)
included only patients naïve to the intervention, 40
(36%) reported no information on the most common
AEs, 65 (59%) reported no information on the methods
used to monitor AEs, and 69 (63%) reported no informa-
tion on effect size variability, such as SDs or CIs.
Sixty-eight (62%) studies investigated broad spectrum
ED (Table 1). Other populations included men with dia-
betes, prostatic cancer, depression, cardiovascular dis-
ease, renal failure, metabolic syndrome, spinal cord
injury and post-traumatic stress syndrome. Median sam-
ple size was 195 (10th to 90th percentile 54 to 385).
Of the studies, 93 (85%), 51 (46%), 93 (85%) and 93
(85%) were assessed with an unclear ROB for allocation
concealment, blinding of participant, blinding of care-
giver and blinding of outcome assessor, respectively.
Zero (0%) studies reported testing of blinding. Of the
Figure 1 PRISMA study flow diagram. ED, erectile dysfunction; PDE-5, phosphodiesterase-5; RCT, randomized controlled trial.
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blinded, 48 (44%) to be inadequately blinded and 57
(52%) to have a low ROB for at least one of four
blinding-related domains. Of 108 requests to authors, 10
(9%) provided additional information on study method-
ology or primary outcomes with estimates of variability.
Nocebo effects
Of the 48 inadequately blinded studies, we could calculate
SDs for 13 studies and randomly added three more studies
with matched SDs. The characteristics and ROB assess-
ments of the studies in the primary analysis can be found
in Additional files 3 and 4. The IIEF-EF domain score in
placebo groups of five adequately blinded trials versus 16
inadequately blinded trials was 1.92 points (95% CI, 0.64to 3.20) versus 1.56 (95% CI, 0.93 to 2.20), respectively.
Unblinding lowered placebo scores (creating a nocebo
effect) by 19% (0.33 points; 95% CI, -0.96 to 1.62) with
moderate heterogeneity (I2 = 61%, P < 0.001; Table 2).
Within-meta-analysis heterogeneity was moderate for
inadequately (I2 = 58%, P = 0.002) and substantial for ad-
equately (I2 = 75%, P = 0.003; Figure 2) blinded studies.
One study (VAR11) accounted for 49% of heterogeneity.
In this 4-week study, participants had 33% chance of re-
ceiving placebo and 72% had prior experience with the
intervention. Another study (SIL15) was underpowered
and mean effect sizes were calculated from skewed data.
Using post-hoc multivariate regression analysis to ex-
plain nocebo effects, controlling for study blinding status
(adequate or inadequate) (ß = -0.10, P = 0.819), studies
Table 1 Overview of characteristics of 110 included
randomized clinical trials
Characteristics
Median sample size (range) 195 (13-817)
Median year of publication (range) 2006 (1998-2012)
Parallel group design 98 (89)
Crossover group design 10 (9)
Study run-in phase with placebo reported 2 (2)
Commercial funding 89 (81)
Single center study 9 (8)
Continent:




North America 23 (21)
Oceania 2 (2)
South America 5 (5)





Broad spectrum 68 (62)
Cardiovascular disease 5 (5)
Depression 5 (5)
Diabetes 9 (8)
Prostatic cancer 6 (6)
Metabolic syndrome 3 (3)
Multiple sclerosis 2 (2)
Post-traumatic stress syndrome 2 (2)
Spinal cord injury 2 (2)
Renal failure 4 (4)
Other 4 (4)
Risk of bias:












Table 1 Overview of characteristics of 110 included














ITT analysis 5 (5)
Balanced baseline prognostic factors 82 (75)
Naïve to intervention 10 (9)
Outcomes
Dichotomeous outcome, GEQ reported 69 (63)
Most common AEs reported* 70 (64)
Methods used to monitor AEs
Prospective or routine monitoring 22 (20)
Spontaneous reporting 13 (12)
Patient checklist, questionnaire or diary 4 (4)
Systematic survey of patients 1 (1)
Not clear 65 (59)
Values are shown as numbers (%) unless stated otherwise. *In the case of
phosphodiesterase-5 (PDE-5) inhibitors, the most common adverse events
(AEs) are headache and flushing. GEQ, Global Efficacy Question; ITT, intention
to treat.
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P = 0.022) showed smaller placebo effects. This model
explained 95% of placebo scores.
Enhanced placebo effects
The intervention effect in five adequately blinded trials
versus 16 inadequately blinded trials was 9.40 (95% CI,
6.96 to 11.83) versus 8.33 (95% CI, 7.29 to 9.37), respect-
ively. Unblinding lowered intervention scores by 11%
(1.0 points; 95% CI, -1.35 to 3.47) with considerable het-
erogeneity (I2 = 88%, P < 0.001). Within-meta-analysis
heterogeneity was considerable for inadequately (I2 =
87%, P < 0.001) and adequately (I2 = 92%, P < 0.001;
Figure 3) blinded studies.
Using post-hoc multivariate regression analysis to ex-
plain intervention effects, controlling for study blinding
status (adequate or inadequate) (ß = -0.27, P = 0.025),
Table 2 Enhanced placebo effects and nocebo effects
IIEF-EF scores for placebo groups IIEF-EF scores for intervention groups
ROB domain No. of studies
(no. of participants)*
Studies with low
ROB (95% CI) (IV)
Studies with unclear or
high ROB (95% CI) (IV)




ROB (95% CI) (IV)
Studies with unclear
or high ROB (95% CI) (IV)
Differenceb
(95% CI)
Summary 4 ROB-domains 5 (1,202)/16 (3,006) 1.92 (0.64 to 3.20) 1.56 (0.93 to 2.20) 0.33 (-0.96 to 1.62) 20 (0.48) 9.40 (6.96 to 11.83) 8.33 (7.29 to 9.37) -1.0 (-1.35 to 3.47)
Allocation concealment 13 (2,487)/48 (11,169) 1.82 (1.14 to 2.50) 1.75 (1.37 to 2.12) 0.07 (-0.8 to 0.93) 58 (0.88) 9.10 (7.94 to 10.26) 8.34 (7.63 to 9.05) 0.78 (-0.65 to 2.20)
Blinding participant 42 (9,159)/19 (3,442) 1.88 (1.45 to 2.31) 1.43 (0.95 to 1.91) 0.42 (-0.33 to 1.16) 64 (0.35) 8.39 (7.69 to 9.10) 8.23 (7.28 to 9.19) 0.16 (-1.02 to1.33)
Blinding caregiver 17 (3,652)/42 (8,652) 1.94 (1.18 to 2.69) 1.77 (1.40 to 2.15) 0.17 (-0.61 to 0.96) 56 (0.54) 8.46 (6.92 to 10.01) 8.64 (8.15 to 9.13) -0.25 (-1.50 to 1.00)
Blinding outcome assessor 17 (3,278)/42 (9,659) 1.82 (0.99 to 2.65) 1.84 (1.48 to 2.21) -0.02 (-0.83 to 0.79) 57 (0.52) 8.59 (7.15 to 10.03) 8.43 (7.80 to 9.06) 0.15 (-1.12 to 1.41)
Impact of unblinding on summary changes from baseline International Index of Erectile Functioning-Erectile Functioning domain (IIEF-EF) scores with 95% CI with estimates of noceboa, enhanced placebob, placebo, and intervention



















Figure 3 Forest plots with International Index of Erectile Functioning-Erectile Functioning domain (IIEF-EF) score in intervention groups
of adequately blinded trials versus inadequately blinded trials.
Figure 2 Forest plots with International Index of Erectile Functioning-Erectile Functioning domain (IIEF-EF) score in placebo groups of
adequately blinded trials versus inadequately blinded trials.
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and more participants experiencing flushing AEs (ß = 0.73,
P <0.001) showed larger intervention effects. This model
explained 83% of intervention scores.Moderators of placebo effects
Using multivariate regression analysis to explain placebo
effects, studies with participants naïve to the intervention
(ß = 0.52, P = 0.012) and a higher proportion of partici-
pants randomized but not analyzed (ß = 0.43, P = 0.033)
showed larger placebo effects. This model explained 79%
of placebo scores (Table 3).
Univariate analysis revealed several patient- and study-
related factors that predicted placebo scores: no prior
experience with intervention (ß = -0.86, P < 0.001), more
participants with prior experience of intervention (ß = -0.55,
P= 0.013), more severe cases of ED (ß = -0.31, P <0.001),
longer duration of studies (ß = 0.56, P= 0.005), more partici-
pants randomized but not analyzed (ß =0.43, P = 0.002),
trials conducted in Asia (ß = 0.42, P = 0.005) and across
continents (ß = 0.36, P = 0.038) have larger placebo effects.
More headache in the intervention group was associ-
ated with smaller placebo scores (ß = -0.28, P = 0.052).
There was a trend towards more flushing in the placebo
group with larger placebo scores (ß = 0.24, P = 0.135) and
higher risk ratios of flushing with smaller placebo effects
(ß = -0.17, P = 0.278).Moderators of intervention effects
Using multivariate regression analysis, studies with larger
placebo scores (ß = 0.32, P < 0.001), more severe cases of
ED (ß = -0.33, P < 0.001), older studies (ß = -0.26, P =
0.002) and larger sample sizes (ß = 0.23, P = 0.003) have
larger intervention effects. This model explained 40% of
intervention scores.
Using univariate regression analysis, more severe cases
of ED (ß = -0.44, P < 0.001) and long duration of study
double blindness (ß = 0.52, P = 0.025) showed larger
intervention scores. Prostate cancer and spinal cord injury
(ß = -0.59, P = 0.003), and later publication year (ß = -0.42,
P < 0.001) showed smaller intervention scores.
More flushing (ß = 0.30, P = 0.071) and larger risk ratio
for flushing (ß = 0.21, P = 0.207) in the intervention group
was associated with larger effect sizes. The effect sizes are
small to medium, but none of these were significant.
For all categorical moderators we performed subgroup
meta-analyses. Forest plots provide absolute estimates of ef-
fects together with figures of heterogeneity (see Additional
file 5). Reporting on methodological data was scarce so we
did not have sufficient studies to present an adjusted effect
estimate for enhanced placebo and nocebo effect, perform
a confirmatory analysis of the primary hypothesis using a
dichotomous outcome (GEQ), several preplanned sensitivityanalyses, assess reporting bias visually, investigate AEs as
possible moderators for enhanced placebo and nocebo ef-
fects, or assess the impact of using placebo during trial
run-in periods.
A post-hoc multivariate regression analysis, using all
the available evidence (110 studies) and with all four
blinding related variables (allocation concealment, blind-
ing of participant, caregiver or outcome assessor), found
these factors did not influence placebo or intervention
effects.
Discussion
Statement of principal findings
Our study found a consistent failure to report on study
blinding in journal publications. Zero out of 205 publica-
tions (ignoring clinical trial and FDA records) provided
sufficient detail to assess allocation concealment, blind-
ing of participants, caregivers and outcome assessors.
Only after contacting authors and skimming clinical trial
register records, we qualified four and one study, re-
spectively, as adequately blinded. Clearly, the blinding
efforts for almost all trials remain unclear.
Our study found a small trend for unblinding in random-
ized clinical trials to underestimate placebo effects (creating
a nocebo effect) and no evidence for the overestimation for
intervention effects (enhanced placebo effects). Given the
statistical uncertainty, lack of power and a large heterogeneity
in the analysis, these findings should be interpreted as in-
conclusive (Table 2).
Secondary analyses provided evidence that prior ex-
perience with the intervention substantially lowered pla-
cebo scores, both expressed as a dichotomous (ß = -0.86,
P < 0.001) and continuous (ß = -0.55, P = 0.013; Table 3)
variable. It is not clear if participants with prior experi-
ence determine their allocation to placebo more effi-
ciently and consequently engender lower expectancies as
to their benefits. Intervention effect estimates were lar-
ger for trials that had larger placebo effects, included
participants with more severe disease, for older trials
and for larger trials. Whether these effects are related to
enhanced expectations is not clear.
Some AEs may have a small effect on both placebo
and intervention effect estimates, but findings were not
consistent across all AEs and could not be confirmed
statistically.
Strengths and weaknesses of the study
Our research methods have been reported transparently
and were open to public scrutiny. All analyses were pre-
specified, were underpinned by scientific rationale and
were performed using appropriate statistical methods.
We found clear evidence that PDE-5 inhibitor studies
for male ED that report a subjective continuous out-
come systematically fail to report on measures taken to













48 -0.11 (0.469) 0.02 (0.918)
% Headache in
intervention group
48 -0.28 (0.052) -0.11 (0.453)
Risk ratio for headache 48 -0.08 (0.569) -0.11 (0.472)
% Flushing in placebo
group
37 0.24 (0.135) 0.02 (0.917)
% Flushing in
intervention group
37 0.10 (0.559) 0.30 (0.071)
Risk ratio for flushing 37 -0.17 (0.278) 0.21 (0.207)
Study related:
Many follow-ups
(≥4 vs 1 or 2)
21 0.05 (0.823) -0.04 (0.867)





15 0.56 (0.005) 0.52 (0.025)
% Randomized not
analyzed
43 0.43 (0.002) 0.25 (0.102)
ITT analysis (yes vs no) 51 -0.07 (0.638) -0.23 (0.094)
Publication year 61 0.02 (0.881) -0.42 (<0.001)
Parallel study design
(yes vs no)
61 -0.10 (0.451) -0.07 (0.589)
Study run-in placebo 2 NA NA
Commercial funding
(yes vs no)




Across continents 19 0.36 (0.038) 0.16 (0.392)
Asia 6 0.42 (0.005) -0.07 (0.667)
Europe 9 0.25 (0.137) 0.21 (0.249)
Single center study
(yes vs no)
56 0.14 (0.308) -0.07 (0.623)
Type of PDE-5 inhibitor
(tadalafil = ref)
59
Sildenafil 30 0.24 (0.105) 0.11 (0.474)
Vardenafil 10 0.17 (0.259) 0.19 (0.199)
% Prior experience
with intervention
14 -0.55 (0.013) -0.05 (0.874)
Patient related:
Prior experience with
intervention (yes vs no)
9 -0.86 (<0.001) -0.10 (0.772)
% Psychogenic
etiology




19 0.04 (0.854) -0.59 (0.003)




58 -0.31 (<0.001) -0.44 (<0.001)




Model on placebo effect
(76% explained)
10****
Naïve to intervention (yes vs no) 0.52 (0.012)
% Randomized not analyzed in
placebo groups
0.44 (0.033)
Model on intervention effect
(40% explained)
107
Placebo effect 0.32 (<0.001)
Baseline disease severity*** -0.33 (<0.001)
Year of publication -0.26 (0.002)
Sample size 0.23 (0.003)
*Negative values represent lowering effects. **Analyses shown only for
continents with more than two studies. ***Higher values on the International
Index of Erectile Functioning-Erectile Functioning domain score questionnaire
represent less severe cases of erectile dysfunction. ****Ten studies reported
investigation of participants with prior experience or naïve to intervention.
ß, standardized regression coëfficient; ITT, intention-to-treat; NA, not assessable
or no data; PDE-5, phosphodiesterase-5; RCT, randomized controlled trial.
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ment was publicly disseminated to improve reporting of
clinical trials - 17 years later, we found that zero papers
report on a recommended minimum set of blinding-
related items [17]. Our review would have benefitted if
reporting of methods in studies were better as this
would have allowed us to evaluate the blinding status
and perform meta-analyses. Only 5 of 110 studies pro-
vided some evidence as having a low ROB for allocation
sequence concealment, blinding of participants, care-
giver and outcome assessor. This small group of ad-
equately blinded studies hampered a thorough analysis
on the existence of nocebo or enhanced placebo effects.
To assess how AEs may moderate outcomes was prob-
lematic; 36% of studies did not report the most common
AEs and, in 59% of studies, the methods used for moni-
toring AEs were unclear. Also, for common, non-specific
AEs, such as headache, it was difficult to assess whether
reported events were due to the intervention or were
present at baseline. The finding that intervention groups
of studies reporting more participants experiencing
headache also gives rise to smaller placebo effects is in
concordance with our unblinding hypotheses. It may be
that those allocated to the intervention become unblinded
and consequently make it easier for study personnel to as-
sociate lack of headache with participants on placebo.
Interpreting such interesting dynamics from our results is
precarious and should only lead to hypothesis generation.
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as a factor that substantially influences outcomes in RCTs.
This study was restricted to the use of PDE-5 inhibitors in
ED, an example of research using subjective outcomes
that is particularly vulnerable to bias [9]. Clearly, the ex-
ternal validity of findings to different medical domains is
limited. We performed many analyses and findings should
be interpreted cautiously because of the risk of some false
positive findings and confounding. As a final limitation of
our study, we evaluated moderator effects within trial
groups. Thus, we separately evaluated placebo and inter-
vention groups and it follows that data were treated as
from single-arm studies and we did not account for the fact
that the analyzed data stem from RCTs. However, in our
secondary multivariate analyses, explaining intervention
effects, we included placebo group scores to account for
randomization.
Quality of the evidence
We included 110 studies that involved 23,877 analyzed
participants. However, only five studies (n = 1,202) were
adequately blinded. Due to poor reporting of SDs, only
16 inadequately (n = 3,006) blinded studies were ana-
lyzed. Using data from the systematic review of Turner
and colleagues on the completeness of reporting for a
random set of RCTs published in medical journals after
the CONSORT statement [18], allocation concealment
was roughly two times more likely to be reported ad-
equately than in our publications, blinding of participants
equally often, blinding of caregiver three times more often
and blinding of outcome assessor two times more often.
Given the lack of adequately blinded studies and poor
reporting of methodological information, our study can-
not provide robust conclusions regarding the existence
of nocebo or enhanced placebo effects in clinical trials
of PDE-5 inhibitors. Mean baseline disease severity and
publication year was comparable for both adequately
and inadequately blinded studies and is assumed to not
confound results. Seven studies included participants
(n = 1,581) who used the drug for the first time, and in
two studies (n = 675) all participants had prior experi-
ence with the intervention. Being naïve to the drug
clearly effected placebo estimates, which was illus-
trated by subgroup analysis with non-overlapping CIs
(95% CI, 2.33 to 3.45, heterogeneity 12%, and -2.06 to
1.84, heterogeneity 82%, respectively). The direction of
the effect is in concordance with our hypothesis:
people who use the drug for the first time may expect
more and experience a larger placebo effect. Conversely,
trial participants who have previous experience with the
drug may be familiar with its adverse effects and may bet-
ter distinguish intervention from placebo. For intervention
estimates, CIs overlap (95% CI, 6.85 to 9.14, heterogeneity
84%, and 7.51 to 9.16, heterogeneity 0%, respectively) andsuggest no direction of effect in concordance with our hy-
pothesis. Overall, there is evidence that placebo effects are
larger for groups of patients that use 3the drug for the first
time. There is no evidence that patients who have previ-
ous experience report enhanced placebo effects.
Potential biases in the review process
We prevented reviewer bias by using rigorous methods
for searching, selecting studies, data collection and ana-
lysis. We published our study-protocol open to every
reader and report on all pre-specified analyses. We per-
formed a comprehensive search of the available evidence
on a routinely measured subjective continuous outcome
in ED. We excluded 63 (36%) studies because this out-
come was not reported, suggesting that selective out-
come reporting may be present. One out of four studies
had baseline imbalance on outcome-related factors. It is
unlikely that all the relevant studies were identified since
half of all clinical trials that have been conducted and
completed have never been published in academic jour-
nals, and trials with positive results are twice as likely to
be published as others [19]. It is therefore expected that
studies with negative findings (small treatment effects)
due to low intervention and/or high placebo effects
could not be included in our analyses and introduced se-
lection bias. Missing data was also a problem within the
available publications. During data collection, no publi-
cations provided sufficient details to assess study blind-
ing. Only after a thorough quest, mainly after repeated
contact with study authors, were 5 of 110 studies quali-
fied as adequately blinded. Additional information from
authors can reflect a response bias, as authors who have
an interest in study blinding may be more willing to pro-
vide study data. Clearly, the blinding status for all but a
few trials is unclear. Given the publication bias, selection
bias and reporting bias, it is likely that we underesti-
mated the nocebo and enhanced placebo effect due to
unblinding in clinical trials.
Agreements and disagreements with other studies or reviews
Methodological meta-epidemiological studies consistently
find that inadequately blinded studies report overesti-
mation of treatment benefits. Inadequate concealment of
the sequence allocation, blinding of participants and out-
come assessor is associated with 15%, 22% and 36% over-
estimation of treatment effects of subjective outcomes [20].
Whether these effects were moderated by placebo or inter-
vention effects was not reported and therefore direct com-
parison with our results is not possible. An RCT for
treating headache compared improvement rated both for
blinded and non-blinded neurologists and patients. A very
large nocebo and an enhanced placebo effect was reported
by unblinded neurologists and patients. Moreover, their
blinded counterparts show larger improvements on placebo
Feys et al. Systematic Reviews 2014, 3:14 Page 12 of 14
http://www.systematicreviewsjournal.com/content/3/1/14than when on the active drug. Interestingly, in agreement
with our hypothesis, neurologists may also have used pres-
ence or absence of side effects to identify treatment alloca-
tion [21]. Adequately blinded studies, defined as studies
with confirmed prospectively measured blinding, show
powerful placebo effects [22]. The use of a placebo inhaler
for asthma symptoms resulted in subjective improvement,
similar to the active drug [23]. In agreement with our find-
ings, asthma treatment with enhanced expectations seems
more powerful for placebo groups [24].
Previously, it was hypothesized that PDE-5 inhibitor-
naïve participants may be more responsive to treatment
[25]. Our findings could not confirm this. We found
intervention effects to be roughly equivalent to those
studies where participants were not naïve to the inter-
vention. In agreement with our findings, previous ex-
perience with an intervention for restless leg syndrome
showed smaller placebo effects, independently from base-
line severity scores, but did not modify intervention effects
[26]. It is widely accepted that placebo effects and baseline
severity underpin intervention effects. For PDE-5 inhibi-
tors, a meta-regression study of treatment effect modifiers
in 13 sildenafil RCTs confirmed this [27]. We could not
replicate their finding that ED duration influences treat-
ment outcome. In agreement with the study, we observed
that publications of more recent trials show smaller inter-
vention effects. The apparent fading of reported interven-
tion effectiveness was also found in a comprehensive
systematic review by Gehr and colleagues [28]. Baseline
disease was found to be the main factor contributing to
this effect whereas sample size did not [28].
Meaning of the study: possible explanations and
implications for clinicians and policymakers
The reasons why publications fail to report blinding-related
information will vary widely. Common sense would con-
clude that poor reporting of blinding is a reflection of the
true absence of blinding. Evidence shows that correctly
blinded studies with subjective, patient reported outcomes
typically show large placebo effects. To demonstrate that
an intervention is effective using a double blinded meth-
odology, there is interest to lower placebo effects and
thereby maximize perceived treatment effects (interven-
tion minus placebo effect). In a broader perspective, poor
reporting may also indicate a lack of interest from profes-
sional bodies such as ethical committees, journal editors,
regulatory agencies and peer reviewers to insist on the im-
portance of adequate reporting.
Clinicians have a duty to communicate the benefits
and harms of PDE-5 inhibitors to their patients suffering
with ED - scientists can help find and disseminate these
answers by conducting methodologically sound studies
and comprehensively reporting the methods and resultsof these studies in publications. Currently, poor reporting
has left clinicians and scientists in the dark, thus holding
back evidence-based progress. Reporting needs vast im-
provements, specifically on methods used for double
blinding. Policy makers can improve this situation by
endorsing legislation that requires all trial results to be
published with adequate minimal reporting as recom-
mended by CONSORT.
Participants in trials who have previous experience with
an intervention may have lower placebo scores because
they can better detect their treatment allocation. Indeed,
changed bodily cues means ‘worse outcome’ and can
lessen their expectations. This can lead to overestimation
of intervention benefits. Participants who are naïve to the
intervention are expected to provide more accurate and
reliable information on intervention benefits and harms.
Efficacy data for first time users of a drug would also im-
prove the external validity of trial findings. Drug approval
authorities should require pharmaceutical companies to
provide trial data from intervention naïve participants that
both approximates real drug benefits more closely and re-
flect expected value in a common, clinical setting.
The reasons why intervention effects deteriorate in
time with smaller sample sizes and lower baseline risk
remain unclear. However, we did notice that more re-
cent trials did include less severe cases of ED, suggesting
baseline risk as a moderating factor.
Conclusions
Our research found a consistent failure to report on
study blinding in journal publications. Poor reporting
made it impossible to assess if studies were indeed
double blinded and to quantify unblinding effects. It is
naïve to assume that a RCT can separate placebo from
real intervention effects, especially for subjective patient-
reported outcomes. Traditional research focus lies on
treatment effects (intervention minus placebo effect),
but loses sight when it comes to underlying non-specific
treatment effects. The current mantra ‘does this work’
should be complemented with ‘what does work’. Also, it
is an unresolved question whether effectiveness results
in unblinding or unblinding results in effectiveness [29].
CONSORT therefore took the decision that it is no lon-
ger required to report on the success of the double-blind
procedure. We feel it withdrew us from the possibility to
more profoundly understand how expectations shape
clinical outcomes. Research should be aimed at under-
standing what patient- and trial-related factors impact
blinding and how this subsequently impacts outcomes. A
systematic review could assess across a range of medical
domains how participants perceived treatment group allo-
cation affects their estimates. It would be of interest to as-
sess if AEs and previous experience provide clues to their
perceived intervention.
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